These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22142825)

  • 1. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
    Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma.
    van Wezel EM; Zwijnenburg D; Zappeij-Kannegieter L; Bus E; van Noesel MM; Molenaar JJ; Versteeg R; Fiocco M; Caron HN; van der Schoot CE; Koster J; Tytgat GA
    J Mol Diagn; 2015 Jan; 17(1):43-52. PubMed ID: 25445214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of PCR targets for monitoring minimal residual disease in neuroblastoma.
    Stutterheim J; Zappeij-Kannegieter L; Ora I; van Sluis PG; Bras J; den Ouden E; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Mol Diagn; 2012; 14(2):168-75. PubMed ID: 22251610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
    Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
    Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
    Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
    Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.
    Bochennek K; Esser R; Lehrnbecher T; Glienke W; Wehner S; Erben S; Soerensen J; Schwabe D; Bader P; Klingebiel T; Koehl U
    Klin Padiatr; 2012 Apr; 224(3):139-42. PubMed ID: 22377741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D1, a novel molecular marker of minimal residual disease, in metastatic neuroblastoma.
    Cheung IY; Feng Y; Vickers A; Gerald W; Cheung NK
    J Mol Diagn; 2007 Apr; 9(2):237-41. PubMed ID: 17384216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma.
    Stutterheim J; Zappeij-Kannegieter L; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Eur J Cancer; 2011 May; 47(8):1193-202. PubMed ID: 21429738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
    Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
    Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
    Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
    Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
    Cheung IY; Cheung NK
    Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients.
    Göbel G; Auer D; Gaugg I; Schneitter A; Lesche R; Müller-Holzner E; Marth C; Daxenbichler G
    Breast Cancer Res Treat; 2011 Nov; 130(1):109-17. PubMed ID: 21221769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic influence of minimal residual disease detected by flow cytometry and peripheral blood stem cell transplantation by CD34+ selection in childhood advanced neuroblastoma.
    Cai JY; Tang YJ; Jiang LM; Pan C; Chen J; Tang JY
    Pediatr Blood Cancer; 2007 Dec; 49(7):952-7. PubMed ID: 17514736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
    Cheung IY; Feng Y; Gerald W; Cheung NK
    Clin Cancer Res; 2008 Nov; 14(21):7020-7. PubMed ID: 18980998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.